reports
HUTCHMED (China) Ltd: 1 director
A director at HUTCHMED (China) Ltd sold 1,300,000 shares at 27.073HKD and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Sean Conroy
Hutchison China MediTech - Elunate receives China NRDL inclusion
Hutchison China MediTech (HCM) has announced that Elunate (fruquintinib capsules) have been included in China’s National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA). Although expected, this is a huge positive as from 1 January 2020 Elunate will be available in all state-run hospital pharmacies and patients on NHSA insurance schemes will be reimbursed. HCM’s innovative oncology assets are making significant progress in China. It has now submitted t...
- Sean Conroy
Hutchison China MediTech - Elunate receives China NRDL inclusion
Hutchison China MediTech (HCM) has announced that Elunate (fruquintinib capsules) have been included in China’s National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA). Although expected, this is a huge positive as from 1 January 2020 Elunate will be available in all state-run hospital pharmacies and patients on NHSA insurance schemes will be reimbursed. HCM’s innovative oncology assets are making significant progress in China. It has now submitted t...
- Sean Conroy
Hutchison China MediTech - Surufatinib NETs solid data at ESMO
Hutchison China MediTech (HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumors (NET). The data support a China NDA submission (imminent), with surufatinib likely to be the first of HCM’s non-partnered assets to reach the market (late 2020). NET tumors are highly prevalent, fragmented in primary origin and are an unmet medical need. Surufatinib could be the first universal drug to treat NET in all patients regardless of tumor su...
- Sean Conroy
Hutchison China MediTech - Surufatinib NETs solid data at ESMO
Hutchison China MediTech (HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumours (NET). The data support a China NDA submission (imminent), with surufatinib likely to be the first of HCM’s non-partnered assets to reach the market (late 2020). NET tumours are highly prevalent, fragmented in primary origin and are an unmet medical need. Surufatinib could be the first universal drug to treat NET in all patients regardless of tumour...
- Susie Jana
Hutchison China MediTech - Onwards and upwards
Hutchison China MediTech (HCM) continues to make progress towards its global strategic aspirations. The interim results highlight the opportunities for Elunate (fruquintinib) capsules in China, with potential inclusion in China’s exclusive NRDL list in Q419, and the breadth of clinical and regulatory catalysts that lie ahead for multiple R&D assets. Surufatinib’s China NDA submission is on track (Q419) and approval in NET would seal HCM’s position as a premier, innovative, China-based onco...
- Susie Jana
Hutchison China MediTech - Onwards and upwards
Hutchison China MediTech (HCM) continues to make progress towards its global strategic aspirations. The interim results highlight the opportunities for Elunate (fruquintinib) capsules in China, with potential inclusion in China’s exclusive NRDL list in Q419, and the breadth of clinical and regulatory catalysts that lie ahead for multiple R&D assets. Surufatinib’s China NDA submission is on track (Q419) and approval in NET would seal HCM’s position as a premier, innovative, China-based onco...
- Susie Jana
Hutchison China MediTech - An emerging global biopharma
Hutchison China MediTech (HCM) has announced positive data that key late-stage asset surufatinib met the primary endpoint of PFS in non-pancreatic at the Phase III interim analysis. This translates to an earlier than expected China NDA submission (H219) and the potential launch of HCM’s first un-partnered asset (early 2021). In China, partner Lilly has launched Elunate (fruquintinib) capsules. Early sales look promising and its potential inclusion on the China NRDL later this year will be defi...
- Susie Jana
Hutchison China MediTech - An emerging global biopharma
Hutchison China MediTech (HCM) has announced positive data that key late-stage asset surufatinib met the primary endpoint of PFS in non-pancreatic at the Phase III interim analysis. This translates to an earlier than expected China NDA submission (H219) and the potential launch of HCM’s first un-partnered asset (early 2021). In China, partner Lilly has launched Elunate (fruquintinib) capsules. Early sales look promising and its potential inclusion on the China NRDL later this year will be defi...
- Franc Gregori
- Lala Gregorek
- Mick Cooper
Chi-Med: Timing is right for a Hong Kong debut
Approval of EGM resolutions paves the way for the IPO of Hutchison China MediTech (Chi-Med) on the Hong Kong Stock Exchange (SEHK) in the coming months. This IPO should enhance Chi-Med’s access to capital, broaden its shareholder base, further raise its profile in its home market, and, importantly, improve liquidity. Liquidity will be further boosted by an associated global offering (size and structure are not yet disclosed), the secondary placement of shares by majority shareholder CK Hutchis...
- Franc Gregori
- Lala Gregorek
- Mick Cooper
- Franc Gregori
- Lala Gregorek
- Mick Cooper
Chi-Med: AACR 2019 - Savolitinib in the spotlight in NSCLC
Data at AACR from two key non-small cell lung cancer (NSCLC) trials has shown that savolitinib has encouraging anti-tumour activity and an acceptable safety profile both as monotherapy in exon 14m/del NSCLC, and in combination with osimertinib in MET+ EGFR-TKI refractory NSCLC. These presentations increase our confidence in Hutchison China MediTech (Chi-Med) and partner AstraZeneca’s ability to launch savolitinib, as the first available selective c-Met inhibitor, in its respective NSCLC settin...
- Franc Gregori
- Lala Gregorek
- Mick Cooper
Hutchison China MediTech: Bringing Global Innovation and China Oncolog...
Hutchison China MediTech’s (Chi-Med’s) noteworthy achievements in FY18 include the landmark approval and launch of Elunate (fruquintinib) in China in 3L mCRC; the continued maturation of the tyrosine kinase inhibitor (TKI) pipeline with multiple assets either in, or approaching, China or Global registrational trials; and significant investment in building the US infrastructure to support the Global Innovation pipeline. 2019 should bring further progress, with a steady stream of clinical cata...
- Franc Gregori
- Lala Gregorek
- Mick Cooper
- Franc Gregori
- Lala Gregorek
- Mick Cooper
Hutchison China MediTech: ASCO GU: promising PRCC data for savo/durva ...
Preliminary CALYPSO study presented at ASCO GU evidenced encouraging efficacy signals for the savolitinib and durvalumab combination in an all-comers papillary renal cell carcinoma (PRCC) population. CALYPSO is an exploratory single arm Phase I/II trial sponsored by Queen Mary University of London, which enrolled both treatment-naïve and previously treated PRCC patients. Hutchison China MediTech (Chi-Med) and partner AstraZeneca are currently reviewing their strategy for savolitinib development...
- Franc Gregori
- Lala Gregorek
- Mick Cooper
Hutchison China MediTech: Global aspirations for a top-class Chinese i...
Hutchison China MediTech (Chi-Med) has achieved the historic Chinese approval of fruquintinib, a first for a novel oncology drug discovered and developed solely in China. With this and its subsequent launch, the company accomplished a key goal, set at its foundation in 2000, of bringing the first of a wave of globally competitive products to market. Chi-Med is now firmly fixed on becoming a leading global biopharmaceutical company. It has a broad pipeline of first- or best-in-class clinical asse...
- Susie Jana
Hutchison China MediTech - Fruquintinib capsules approved in China
Hutchison China MediTech’s (HCM) lead TKI asset, fruquintinib, has received China registration approval from the National Medical Products Administration of China (NMPA) for the treatment of CRC (third line). The approval serves as a major validation of the R&D innovation strategy, which HCM has cultivated over the years. This is the first innovative drug for an oncology indication, discovered and developed in China through a randomized clinical trial, to be unconditionally approved in that co...
- Susie Jana
Hutchison China MediTech - Establishing a global operational presence
Highlights from Hutchison China MediTech’s (HCM) H118 results relate to the substantial pipeline-related newsflow expected in 2018/19, the recent expansion of its US and international operations (which will enable HCM to execute its international R&D and commercialization strategies) plus strong operational and financial performance by the China commercial platform division. Fruquintinib (third-line CRC) remains on track to launch in China by year end (approval decision expected by the CNDA in...
- Susie Jana
Hutchison China MediTech - Establishing a global operational presence
Highlights from Hutchison China MediTech’s (HCM) H118 results relate to the substantial pipeline-related newsflow expected in 2018/19, the recent expansion of its US and international operations (which will enable HCM to execute its international R&D and commercialisation strategies) plus strong operational and financial performance by the China commercial platform division. Fruquintinib (third-line CRC) remains on track to launch in China by year end (approval decision expected by the CNDA in...
- Susie Jana
Hutchison China MediTech - Jewels in the crown
Key near-term value drivers include newsflow from partnered assets savolitinib (AZN globally) and fruquintinib (LLY in China). By year end, we anticipate the China FDA to approve fruquintinib (3L CRC). The molecular epidemiology study (MES) data on savolitinib in PRCC could support a US NDA submission (possible breakthrough therapy designation, BTD). Both products have blockbuster potential; as combination therapies in cancer drive overall uptake of targeted therapies. Beyond this we expect prog...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.